摘要
目的总结伏立康唑治疗光滑假丝酵母菌肺部感染老年患者的临床疗效。方法收集2008年9月-2011年4月使用伏立康唑治疗光滑假丝酵母菌肺部感染患者临床资料,对其临床疗效和预后进行回顾性总结分析。结果伏立康唑治疗光滑假丝酵母菌肺部感染患者临床总有效率75.9%,真菌清除率65.5%,死亡7例;预后分析显示APACHEⅡ是影响预后的独立危险因素(P=0.013)。结论伏立康唑治疗老年患者光滑假丝酵母菌肺部感染临床疗效安全有效。
OBJECTIVE To observe the efficacy of voriconazole in treatment of Candida glabrata pulmonary infection in elder patients. METHODS Data were retrospectively collected from the elder patients with C. glabrata pulmonary infection treated by voriconazole from Sep 2008 to Apr 2011. The drug clinical efficacy and outcomes were reviewed. RESULTS Voriconazole showed good efficacy for the elder patients with C. glabrata pulmonary infection. The total clinical cure rate was 75. 9%. Fungal eradication rate was 65. 5%. APACHE Ⅱ was independent factor of clinical outcome （P= 0. 013）. Seven patients were died. CONCLUSION Our analysis suggests that voriconazole may be an effective and safe treatment for the elder patients with Candida glabrata pulmonary infection.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2011年第21期4572-4573,4623,共3页
Chinese Journal of Nosocomiology
